Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update

Mar 22, 2022 | Press Releases

Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass., March 22, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next...

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022

Mar 8, 2022 | Press Releases

MARLBOROUGH, Mass., March 8, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

Feb 22, 2022 | Press Releases

Advancement of additional studies is based on positive results from in vitro studies and the ongoing COVID-19 pandemicMARLBOROUGH, Mass., Feb. 22, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next...

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Jan 11, 2022 | Press Releases

French regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first quarter of 2022 MARLBOROUGH, Mass., Jan. 11, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next...

Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference

Jan 3, 2022 | Press Releases

MARLBOROUGH, Mass., Jan. 3, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...